MedTrace Logo

Multimodal Imaging in Rectal Cancer & Pancreatic Cancer

NCT06395337 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2024-05-02

No results posted yet for this study

Summary

Most digestive cancers show (over)expression of the tumour marker carcinoembryonic antigen (CEA). Therefore, interest in CEA-targeting tracers has increased over the past years. CEA-targeting tracers can be used for preoperative, intra-operative and postoperative imaging purposes. This study focusses on both preoperative and intraoperative multimodal imaging and image-guided surgery in patients with rectal cancer or pancreatic cancer.

Conditions

Interventions

DRUG

[111In]In-DOTA-ANTI-CEA antibody injection

tracer injection

RADIATION

SPECT/CT scan

abdominal and thoracic SPECT/CT scan

PROCEDURE

Resection surgery

oncological resection surgery will be performed extended with the use of dual-modality imaging.

Sponsors & Collaborators

  • Leiden University Medical Center

    collaborator OTHER

  • Radboud University Medical Center

    lead OTHER

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-05-02
Primary Completion
2025-05-02
Completion
2025-06-02

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06395337 on ClinicalTrials.gov